The appraisal committee has prepared final draft guidance (FDG) on crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) and submitted it to NICE. The FDG has ...
It is the only ROS1 TKI with FDA breakthrough therapy designation for locally advanced or metastatic ROS1-positive NSCLC. The FDA has granted priority review to an NDA for taletrectinib in the ...
In December 2024, Dovbleron was approved by the NMPA for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC ... to see that Dovbleron ...
(NYSE: NUVB) submitted an NDA for taletrectinib to the U.S. FDA for the treatment of patients with advanced ROS1-positive NSCLC (line agnostic, full approval ... References [i] Zhang et al. Prevalence ...